Nikon’s First European Nikon BioImaging Lab Now Open in Leiden
5.10.2021 07:00:00 EEST | Business Wire | Press release
Nikon Europe B.V. has announced that its first European Nikon BioImaging Lab (NBIL) based in the prestigious Leiden Bio Science Park (LBSP) is now officially open.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005909/en/
Speakers at Nikon BioImaging Lab Inauguration ceremony (Photo: Business Wire)
The official opening took place on September 22nd with a welcome by Ziryan Othman, Team Leader Biotechnology Solutions, Nikon Europe Healthcare Division, followed by addresses by representatives of the organisations involved in helping Nikon Europe B.V. locate and develop the partnership with the Leiden Bio Science Park: Paul Dirkse, Vice Mayor of the City of Leiden; Hilde van der Meer, Commissioner, Netherlands Foreign Investment Agency; Chris van Voorden, Director Foreign Investments of InnovationQuarter; Ida Haisma, Director of Stichting Leiden Bio Science Park; Thijs de Kleer, Director of Biopartner Leiden, and Amito Haarhuis, Director of Rijksmuseum Boerhaave. Bo Kajiwara, Corporate Vice President, Nikon Corporation, Director & President, Nikon Europe B.V. led the opening program for Nikon Europe B.V.
The inauguration and ribbon cutting took place with a symbolic transfer of the famous 17th century van Leeuwenhoek’s microscope, by Amito Haarhuis. World famous for his pioneering work and discoveries in microscopy, Antonie van Leeuwenhoek developed this single-lens microscope, which proved capable of more powerful magnification than other lenses.
Takaharu Sasaoka, Director and Executive Vice President, Healthcare Business Head, Nikon Europe B.V., appreciates the symbolism of the microscope transfer, “It is very appropriate that Nikon, with over 100 years of expertise in optical technology, should open its first European Nikon BioImaging Lab (NBIL-Leiden) here in the Netherlands, the home of Antonie van Leeuwenhoek, the ‘father of microbiology’, whose systematic and extensive research laid the foundations of medical and scientific research. Our mission also is to advance healthcare and provide a better quality of life.
“We are very excited to be located here in the Leiden Bio Science Park, the largest life sciences cluster in the Netherlands, and I would like to thank all the organisations that helped Nikon Europe B.V. locate and develop this partnership. Following the success of our Nikon BioImaging Labs in the US and Japan, NBIL-Leiden will provide services for microscope-based imaging and analysis to the European biotech, pharma, and larger research communities. We are more than a core facility – our full-service capabilities include not only access to Nikon’s innovative microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services.”
Daniel Ciepielewski, General Manager, Healthcare Division, Nikon Europe B.V., explains further, “NBIL-Leiden provides full-service imaging, data analysis, and cell cultures using cutting-edge Nikon microscope systems and software solutions, including the new laser scanning confocal AX R, the incubated high content imaging platform LIPSI, deep learning software NIS.ai, research inverted microscope Ti2-E, and compact live-cell imaging microscope BioStudio-T. Unlike other imaging facilities the lab offers full-service cell culture capabilities – our experienced staff is equipped to handle cell thawing, maintenance, expansion, differentiation, and other essential operations.
“The level of service and involvement of the lab is determined individually for each client based on need. Some need only access to equipment and are capable of data acquisition/analysis on their own, while others may require full-service imaging and analysis support. Additional applications include high content imaging and analysis, 3D imaging, fluorescence imaging, high-resolution imaging, color imaging, label-free imaging, cell screening and high throughput imaging, among others. NBIL-Leiden is now open, providing expert imaging support – on demand.”
Nikon Europe B.V. is grateful to InnovationQuarter, the regional economic development agency for the Province of Zuid-Holland, which assisted us in finding the right location and helped coordinate communication to develop the partnership with the Leiden Bio Science Park.
Nikon Europe B.V. is also grateful to the following contributing companies who have partnered with NBIL-Leiden: Clean Air Baker, PHC, Crest Optics, Photometrics, CoolLed, and Precipoint.
For further information, please contact: NBIL.EU@nikon.com
Or please visit www.microscope.healthcare.nikon.com/en_EU/products/cell-screening/nbil.
About Nikon Europe B.V.
Nikon Europe B.V. is the European microscopy arm of Nikon Healthcare Business Unit, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. For more information, please visit www.microscope.healthcare.nikon.com/en_EU.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005909/en/
Contact information
For media information:
Ziryan Othman
Ziryan.Othman@nikon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
emnify named a Visionary in the 2026 Gartner ® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide7.5.2026 18:00:00 EEST | Press release
emnify, a global provider of cloud-native IoT connectivity solutions, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507642325/en/ emnify named a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. Get the report As a first-time recognized vendor, emnify believes this recognition reflects its forward-looking approach to IoT connectivity, building a platform designed to anticipate where enterprise needs are heading rather than replicating the connectivity models of the past. "We feel being named a Visionary in our first appearance in the Gartner® Magic Quadrant™ recognizes our deliberate strategy of the last decade: from owning our core network and pioneering satellite-cellular convergence on a single SIM, to embedding fine-tuned AI models
UAE Commits $49bn to Local Manufacturers7.5.2026 17:00:00 EEST | Press release
The United Arab Emirates (UAE) pledged $49 billion in industrial procurement opportunities on Monday and announced plans to localize more than 5,000 products as the Gulf state doubled down on its industrial sovereignty agenda. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507855698/en/ UAE commits $49bn to local manufacturers (Photo: AETOSWire) Dr. Sultan Al Jaber, UAE Minister of Industry and Advanced Technology, made the announcement at the opening of the fifth edition of Make it in the Emirates, which follows a period that has tested the region. “History remembers the challenges nations face. But it also remembers how nations respond to them and what they build next,” he said. TA’ZIZ announced $40.5 billion worth of agreements aimed at expanding UAE chemical production capacity. The opportunities include offtakes and $2 billion of financing for the UAE’s first world-scale methanol plant. A $270 million National Indust
Andersen Consulting Strengthens Organizational Transformation Capabilities with Afiniti7.5.2026 16:30:00 EEST | Press release
Andersen Consulting announces a Collaboration Agreement with Afiniti, a global business transformation consultancy headquartered in the United Kingdom that helps organizations deliver and sustain complex change programs. Founded in 2003, Afiniti is a global business change consultancy based in the UK and U.S., supporting clients through complex transformation across people, process, systems, and data, and bringing change to life through creative consulting services. The firm primarily serves highly regulated, safety-driven, and asset-intensive organizations with large, geographically dispersed workforces across sectors including energy, utilities, life sciences, transport, and construction. Afiniti works with well-known brands to deliver end-to-end expertise across organizational, digital and AI, cultural, and operating model transformation, particularly in complex scenarios such as mergers and acquisitions, large-scale technology adoption, and underperforming change programs that have
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
